
- Volume 0 0
Aromasin Offers Better Breast Cancer Survival Rates
The Intergroup Exemestane Study(IES) yielded data showing that hormone-sensitive postmenopausal earlybreast cancer patients who switchedfrom tamoxifen to Aromasin (exemestane)were 17% more likely to be aliveand 25% less likely to see their cancerreturn than patients who remained ontamoxifen for 5 years. These study findingsstem from almost 5 years of followupof the IES trial, a large, randomized,double-blind, multinational trial comparing2352 patients taking Aromasin followingtamoxifen therapy with 2372patients remaining on tamoxifen therapyfor 5 years. The IES produced earlyresults that prompted the FDA andEuropean regulatory approvals forAromasin. These findings showed that85% of patients in the trial were postmenopausalhormone receptor-positive,and those who switched to Aromasinreduced their risk of breast cancer recurrenceby 35%, compared with the tamoxifengroup. Previously, no difference insurvival rates had been noted. Sideeffects were mild to moderate andincluded hot flashes, fatigue, arthralgia,headache, insomnia, and increasedsweating.
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.
Articles in this issue
over 20 years ago
Questions and Answers About Dry Mouthover 20 years ago
Kidney Stoneover 20 years ago
Rx Productsover 20 years ago
can you READ these Rxs?over 20 years ago
OTC Productsover 20 years ago
Discrimination in Design of an Rx Drug Insurance Program?over 20 years ago
compounding HOTLINEover 20 years ago
A Calming Influence: An Analysis of ADHD Treatmentsover 20 years ago
Carbinoxamine Products Still Within Reachover 20 years ago
Wal-Mart Pharmacist of the Year: Indispensable to Her CommunityRelated to this article








